106 related articles for article (PubMed ID: 15233293)
1. Overexpression of c-erbB-2 oncoprotein and associated pathobiological factors in invasive primary breast cancer.
Ray A; Sharma BK; Kaur S; Sharma S; Sharma JK
Indian J Exp Biol; 2004 Mar; 42(3):253-8. PubMed ID: 15233293
[TBL] [Abstract][Full Text] [Related]
2. Distribution of prognostically unfavourable product of c-erbB-2 oncogene and EGF-R in carcinomas of the breast and uterine cervix.
Ray A; Naik SL; Sharma BK
Indian J Physiol Pharmacol; 2002 Oct; 46(4):423-33. PubMed ID: 12683217
[TBL] [Abstract][Full Text] [Related]
3. Adrenocorticotropic hormone and growth factor receptors in breast cancer.
Ray A; Ratnakar N; Murthy NS; Sharma BK
Indian J Exp Biol; 2000 Jul; 38(7):663-8. PubMed ID: 11215308
[TBL] [Abstract][Full Text] [Related]
4. Combined overexpression of c-erbB-2 protein and epidermal growth factor receptor (EGF-R) could be predictive of early and long-term outcome in human breast cancer: a pilot study.
Delarue JC; Terrier P; Terrier-Lacombe MJ; Mouriesse H; Gotteland M; May-Levin F
Bull Cancer; 1994 Dec; 81(12):1067-77. PubMed ID: 7742595
[TBL] [Abstract][Full Text] [Related]
5. Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes.
Harłoziñska A; Bar JK; Wenderski R; Bebenek M
In Vivo; 1996; 10(2):217-22. PubMed ID: 8744803
[TBL] [Abstract][Full Text] [Related]
6. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein.
Looi LM; Cheah PL
Malays J Pathol; 1998 Jun; 20(1):19-23. PubMed ID: 10879259
[TBL] [Abstract][Full Text] [Related]
7. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
8. [Correlation of Her-2 overexpression with endocrine status and response to tamoxifen treatment in patients with breast cancer].
Zhang J; Zhang JH; Liu Y; Hao XM; Fang ZX; Li SL
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(46):3268-71. PubMed ID: 18396622
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
Sharma BK; Ray A; Kaur S; Gupta S
Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149
[TBL] [Abstract][Full Text] [Related]
10. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I
Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434
[TBL] [Abstract][Full Text] [Related]
11. Comparison of HER-2/neu, ER and PCNA expression in premenopausal and postmenopausal patients with breast carcinoma.
Zheng W; Zheng J; Ma L; Meng F; Huang L; Ma D
APMIS; 2005 Mar; 113(3):175-81. PubMed ID: 15799760
[TBL] [Abstract][Full Text] [Related]
12. Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.
Prisack HB; Karreman C; Modlich O; Audretsch W; Danae M; Rezai M; Bojar H
Anticancer Res; 2005; 25(6C):4615-21. PubMed ID: 16334152
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of TGF-alpha, EGF-R, c-erbB-2, c-H-ras, c-myc, estrogen and progesterone in benign and malignant human breast lesions: a concomitant expression.
Spaventi R; Kamenjicki E; Pecina N; Grazio S; Grazio S; Pavelic J; Kusic B; Cvrtila D; Danilovic Z; Spaventi S
In Vivo; 1994; 8(2):183-9. PubMed ID: 7919121
[TBL] [Abstract][Full Text] [Related]
14. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
15. The correlation of c-erbB-2 oncoprotein and established prognostic factors in human breast cancer.
Sütterlin MW; Haller A; Gassel AM; Peters K; Caffier H; Dietl J
Anticancer Res; 2000; 20(6D):5083-8. PubMed ID: 11326673
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of c-erbB-2 oncoprotein and EGF-R in pre- and postmenopausal breast cancer.
Ratnakar N; Sharma BK; Chaturvedi KU; Kaur S; Naik SL; Ray A
APMIS; 1998 Nov; 106(11):1075-80. PubMed ID: 9890270
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer.
Homaei-Shandiz F; Ghavam-Nassiri MR; Sharifi N; Homaei-Shandiz AH; Taghizadeh-Kermani A; Torshizi SA; Ghafarzadegan K
Saudi Med J; 2006 Dec; 27(12):1810-4. PubMed ID: 17143354
[TBL] [Abstract][Full Text] [Related]
18. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
[TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
20. The importance of prognostic factors in premenopausal women with breast cancer.
Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]